Skip to content

A randomized, controlled, multicentre clinical study of optimizing Yantiao prescription in the treatment of septic shock

A randomized, controlled, multicentre clinical study of optimizing Yantiao prescription in the treatment of septic shock

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043735
Enrollment
Unknown
Registered
2021-02-27
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock

Interventions

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-80 years old; 2. Patients with septic shock; 3. Patients with acute attack within 3 days.

Exclusion criteria

Exclusion criteria: 1. Patients with allergic constitution or allergic to known components of the drug; 2. Mental patients; 3. Subjects with intestinal obstruction caused by other causes; 4. Patients with malignant tumor; 5. The subjects who did not meet the inclusion criteria, did not use drugs according to the regulations, could not determine the efficacy or incomplete information, which affected the efficacy or safety judgment.

Design outcomes

Primary

MeasureTime frame
Cumulative survival at day 28;

Secondary

MeasureTime frame
Blood routine examination;C-reactive protein;blood lactate;total bilirubin;Alanine transaminase;cholinesterase;procalcitonin;Tumor necrosis factor-a;interleukin-6;Interleukin-8;SOFA score;APACHE II score;Venous ultrasound of lower extremity;echocardiography;TCM syndrome scores;

Countries

China

Contacts

Public ContactWang Qian

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine

lingqihua@hotmail.com+86 13681679033

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026